The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T‐cell lymphoma, nasal type, in the United States
Open Access
- 5 April 2017
- Vol. 123 (16), 3176-3185
- https://doi.org/10.1002/cncr.30697
Abstract
BACKGROUND Extranodal natural killer T‐cell lymphoma, nasal‐type (NKTCL), is a rare malignancy in Western populations and is thus challenging for standardization of care and a prospective study. This study was aimed at defining patterns of care for NKTCL in the context of radiotherapy (RT) use and dose selection in the United States. METHODS Six hundred forty‐two stage I‐II NKTCL patients from 1998 to 2012 were identified from the National Cancer Data Base. Binary logistic regression analyses were performed to identify sociodemographic, treatment, and tumor characteristics predictive of the treatment selection and RT dose. Overall survival (OS) analyses were completed with the Kaplan‐Meier and Cox multivariate methods, including a propensity score adjustment for a potential indication bias. RESULTS Of the 642 included NKTCL patients, 70% were at stage I, 79% were white, and 66% were ≤ 60 years old. Fifty‐five percent received chemotherapy plus RT, 19% received RT alone, and 27% received chemotherapy alone. The median RT dose was 50 Gy (interquartile range, 43.2‐54 Gy), 37% received < 45 Gy, and 43% received < 50 Gy. A multivariate survival analysis showed improved OS in comparison with chemotherapy alone for RT alone at ≥50 Gy (hazard ratio [HR], 0.41; 95% confidence interval [CI], 0.23‐0.70; P < .01), for chemotherapy plus RT at P < .01), and for chemotherapy plus RT at ≥50 Gy (HR, 0.41; 95% CI, 0.27‐0.63; P < .01). CONCLUSIONS Stage I‐II NKTCL patients in the United States commonly receive chemotherapy alone or suboptimal‐dose RT. The omission of RT or the use of suboptimal RT is negatively associated with OS. Efforts to continue improving evidenced‐based management are warranted. Cancer 2017;123:3176–85. © 2017 American Cancer Society.Keywords
This publication has 26 references indexed in Scilit:
- Re-Examining the Role of Radiation Therapy for Diffuse Large B-Cell Lymphoma in the Modern EraJournal of Clinical Oncology, 2016
- Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2015
- Modern Radiation Therapy for Extranodal Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology GroupInternational Journal of Radiation Oncology*Biology*Physics, 2015
- Early radiotherapy has an essential role for improving survival in patients with stage I-II nasal-type of NK/T cell lymphoma treated with l-asparaginase-containing chemotherapy—a single institution experienceAnnals of Hematology, 2014
- Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trialRadiotherapy and Oncology, 2011
- Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma ProjectBlood, 2009
- Early or Up-Front Radiotherapy Improved Survival of Localized Extranodal NK/T-Cell Lymphoma, Nasal-Type in the Upper Aerodigestive TractInternational Journal of Radiation Oncology*Biology*Physics, 2008
- Extranodal natural killer/T‐cell lymphoma, nasal typeCancer, 2005
- CHOP followed by involved field radiation: Is it optimal for localized nasal natural killer/T-cell lymphoma?Annals of Oncology, 2001
- Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell LymphomasThe American Journal of Surgical Pathology, 1996